Management of nonischemic-dilated cardiomyopathies in clinical practice: a position paper of the working group on myocardial and pericardial diseases of Italian Society of Cardiology.
Cardiac Imaging Techniques
/ standards
Cardiology
/ standards
Cardiomyopathy, Dilated
/ diagnosis
Clinical Decision-Making
Consensus
Cooperative Behavior
Delivery of Health Care, Integrated
/ standards
Heart Function Tests
/ standards
Humans
Interdisciplinary Communication
Patient Care Team
/ standards
Predictive Value of Tests
Prognosis
Referral and Consultation
/ standards
Risk Factors
Time Factors
Journal
Journal of cardiovascular medicine (Hagerstown, Md.)
ISSN: 1558-2035
Titre abrégé: J Cardiovasc Med (Hagerstown)
Pays: United States
ID NLM: 101259752
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
pubmed:
3
8
2020
medline:
20
5
2021
entrez:
3
8
2020
Statut:
ppublish
Résumé
: Nonischemic-dilated cardiomyopathy (NIDCM) is an entity that gathers extremely heterogeneous diseases. This awareness, although leading to continuous improvement in survival, has increased the complexity of NIDCM patients' management. Even though the endorsed 'red-flags' approach helps clinicians in pursuing an accurate etiological definition in clinical practice, it is not clear when and how peripheral centers should interact with referral centers with specific expertise in challenging scenarios (e.g. postmyocarditis and genetically determined dilated cardiomyopathy) and with easier access to second-line diagnostic tools and therapies. This position paper will summarize each step in NIDCM management, highlighting the multiple interactions between peripheral and referral centers, from first-line diagnostic workup and therapy to advanced heart failure management and long-term follow-up.
Identifiants
pubmed: 32740436
doi: 10.2459/JCM.0000000000001050
pii: 01244665-202012000-00002
doi:
Types de publication
Journal Article
Practice Guideline
Langues
eng
Sous-ensembles de citation
IM
Pagination
927-943Références
Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; quality of care and outcomes research and function. Circulation 2006; 113:1807–1816.
Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008; 29:270–276.
Pinto YM, Elliott PM, Arbustini E, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic nondilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J 2016; 37:1850–1858.
Merlo M, Pivetta A, Pinamonti B, et al. Long-term prognostic impact of therapeutic strategies in patients with idiopathic dilated cardiomyopathy: changing mortality over the last 30 years. Eur J Hear Fail 2014; 16:317–324.
Japp AG, Gulati A, Cook SA, Cowie MR, Prasad SK. The diagnosis and evaluation of dilated cardiomyopathy. J Am Coll Cardiol 2016; 67:2996–3010.
Seferović PM, Polovina M, Bauersachs J, et al. Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2019; 21:553–576.
Mahon NG, Murphy RT, MacRae CA, Caforio ALP, Elliott PM, McKenna WJ. Echocardiographic evaluation in asymptomatic relatives of patients with dilated cardiomyopathy. Ann Intern Med 2005; 143:108.
Merlo M, Cannatà A, Gobbo M, Stolfo D, Elliott PM, Sinagra G. Evolving concepts in dilated cardiomyopathy. Eur J Heart Fail 2018; 20:228–239.
Felker GM, Shaw LK, O’Connor CM. A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol 2002; 39:210–218.
Rapezzi C, Arbustini E, Caforio AL, et al. Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis: a position statement from the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013; 34:1448–1458.
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37:2129–2200.
Mestroni L, Maisch B, McKenna WJ, et al. Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy. Eur Heart J 1999; 20:93–102.
Hershberger RE, Givertz MM, Ho CY, et al. Genetic evaluation of cardiomyopathy – a Heart Failure Society of America Practice Guideline. J Card Fail 2018; 24:281–302.
Anastasakis A, Basso C. Primary’ dilated hearts. Int J Cardiol 2018; 257:366–370.
Bobbo M, Pinamonti B, Merlo M, et al. Comparison of patient characteristics and course of hypertensive hypokinetic cardiomyopathy versus idiopathic dilated cardiomyopathy. Am J Cardiol 2017; 119:483–489.
Kenigsberg B, Wellstein A, Barac A. Left ventricular dysfunction in cancer treatment: is it relevant? JACC Hear Fail 2018; 6:87–95.
Anzini M, Merlo M, Sabbadini G, et al. Long-term evolution and prognostic stratification of biopsy-proven active myocarditis. Circulation 2013; 128:2384–2394.
Caforio ALP, Adler Y, Agostini C, et al. Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease. Eur Heart J 2017; 38:2649–2662.
Caforio ALP, Mahon NG, Baig MK, et al. Prospective familial assessment in dilated cardiomyopathy: cardiac autoantibodies predict disease development in asymptomatic relatives. Circulation 2007; 115:76–83.
Mora G. Chagas cardiomyopathy. E J Cardiol Pract 2016; 14:31.
Requena-Méndez A, Aldasoro E, de Lazzari E, et al. Prevalence of chagas disease in Latin-American migrants living in europe: a systematic review and meta-analysis. PLoS Negl Trop Dis 2015; 9:e0003540.
Razvi S, Jabbar A, Pingitore A, et al. Thyroid hormones and cardiovascular function and diseases. J Am Coll Cardiol 2018; 71:1781–1796.
Wang W, Guan H, Fang W, et al. Free triiodothyronine level correlates with myocardial injury and prognosis in idiopathic dilated cardiomyopathy: evidence from cardiac MRI and SPECT/PET imaging. Sci Rep 2016; 6:39811.
Pearce SHS, Brabant G, Duntas LH, et al. 2013 ETA guideline: management of subclinical hypothyroidism. Eur Thyroid J 2013; 2:215–228.
Jabbar A, Pingitore A, Pearce SH, Zaman A, Iervasi G, Razvi S. Thyroid hormones and cardiovascular disease. Nat Rev Cardiol 2017; 14:39–55.
Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994; 331:1249–1252.
Huizar JF, Ellenbogen KA, Tan AY, Kaszala K. Arrhythmia-induced cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 2019; 73:2328–2344.
Cory CR, McCutcheon LJ, O’Grady M, Pang AW, Geiger JD, O’Brien PJ. Compensatory downregulation of myocardial Ca channel in SR from dogs with heart failure. Am J Physiol 1993; 264 (3 Pt 2):H926–H937.
Huizar JF, Kaszala K, Potfay J, et al. Left ventricular systolic dysfunction induced by ventricular ectopy: a novel model for premature ventricular contraction-induced cardiomyopathy. Circ Arrhythmia Electrophysiol 2011; 4:543–549.
Sanna GD, Merlo M, Moccia E, et al. Left bundle branch block-induced cardiomyopathy: a diagnostic proposal for a poorly explored pathological entity. Int J Cardiol 2020; 299:199–205.
Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 2018; 378:417–427.
Sliwa K, Mebazaa A, Hilfiker-Kleiner D, et al. Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM): EURObservational Research Programme in Conjunction With the Heart Failure Association of the European Society of Cardiology Study Group on PPCM. Eur J Heart Fail 2017; 19:1131–1141.
Jackson AM, Dalzell JR, Walker NL, Coats CJ, Jhund PS, Petrie MC. Peripartum cardiomyopathy: diagnosis and management. Heart 2018; 104:779–786.
van Spaendonck-Zwarts KY, van Tintelen JP, van Veldhuisen DJ, et al. Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. Circulation 2010; 121:2169–2175.
Ware JS, Li J, Mazaika E, et al. Shared genetic predisposition in peripartum and dilated cardiomyopathies. N Engl J Med 2016; 374:233–241.
Ferrero P, Piazza I, Grosu A, Brambilla P, Sironi S, Senni M. QRS fragmentation as possible new marker of fibrosis in patients with myocarditis: preliminary validation with cardiac magnetic resonance. Eur J Heart Fail 2019; 21:1160–1161.
Sze E, Samad Z, Dunning A, et al. Impaired recovery of left ventricular function in patients with cardiomyopathy and left bundle branch block. J Am Coll Cardiol 2018; 71:306–317.
Ahn M-S, Kim J-B, Joung B, Lee M-H, Kim S-S. Prognostic implications of fragmented QRS and its relationship with delayed contrast-enhanced cardiovascular magnetic resonance imaging in patients with non-ischemic dilated cardiomyopathy. Int J Cardiol 2013; 167:1417–1422.
Merlo M, Zaffalon D, Stolfo D, et al. ECG in dilated cardiomyopathy: specific findings and long-term prognostic significance. J Cardiovasc Med (Hangerstown) 2019; 20:450–458.
Gigli M, Stolfo D, Merlo M, et al. Insights into mildly dilated cardiomyopathy: temporal evolution and long-term prognosis. Eur J Heart Fail 2017; 19:531–539.
Dini FL, Cortigiani L, Baldini U, et al. Prognostic value of left atrial enlargement in patients with idiopathic dilated cardiomyopathy and ischemic cardiomyopathy. Am J Cardiol 2002; 89:518–523.
Stolfo D, Merlo M, Pinamonti B, et al. Early improvement of functional mitral regurgitation in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 2015; 115:1137–1143.
Merlo M, Gobbo M, Stolfo D, et al. The prognostic impact of the evolution of RV function in idiopathic DCM. JACC Cardiovasc Imaging 2016; 9:1034–1042.
Wunderlich NC, Siegel RJ. Peri-interventional echo assessment for the MitraClip procedure. Eur Hear J Cardiovasc Imaging 2013; 14:935–949.
Lakdawala NK, Thune JJ, Colan SD, et al. Subtle abnormalities in contractile function are an early manifestation of sarcomere mutations in dilated cardiomyopathy. Circ Cardiovasc Genet 2012; 5:503–510.
Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol 2014; 63:2751–2768.
McMurray JJV, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371:993–1004.
Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin–neprilysin inhibition in acute decompensated heart failure. N Engl J Med 2018; 380:539–548.
Bardy GH, Lee KL, Mark DB, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2005; 352:225–237.
Køber La, Thune JJ, Nielsen JC, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med 2017; 18:54–56.
Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009; 361:1329–1338.
Bozkurt B, Colvin M, Cook J, et al. Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association. Circulation 2016; 134:e579–e646.
Patel AR, Kramer CM. Role of cardiac magnetic resonance in the diagnosis and prognosis of non-ischemic cardiomyopathy. JACC Cardiovasc Imaging 2018; 10:1180–1193.
Abbasi SA, Ertel A, Shah RV, et al. Impact of cardiovascular magnetic resonance on management and clinical decision-making in heart failure patients. J Cardiovasc Magn Reson 2013; 15:89.
Chirstopher MK. Role of cardiac MR imaging in cardiomyopathies. J Nucl Med 2015; 56:39–45.
McCrohon JA, Moon JCC, Prasad SK, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation 2003; 108:54–59.
Mahrholdt H, Wagner A, Judd RM, Sechtem UKR. Assessment of myocardial delayed enhancement with cardiac computed tomography in cardiomyopathies: a prospective comparison with delayed enhancement cardiac magnetic resonance imaging. Eur Heart J 2005; 26:1461–1474.
Beck KS, Jeong SY, Lee KY, Chang K, Jung JI. Native T1 mapping demonstrating apical thrombi in eosinophilic myocarditis associated with Churg-Strauss syndrome. Korean Circ J 2016; 46:882–885.
Iles L, Pfluger H, Lefkovits L, et al. Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death. J Am Coll Cardiol 2011; 57:821–828.
Zorzi A, Perazzolo Marra M, Rigato I, et al. Nonischemic left ventricular scar as a substrate of life-threatening ventricular arrhythmias and sudden cardiac death in competitive athletes. Circ Arrhythm Electrophysiol 2016; 9:e004229.
Gulati A, Jabbour A, Ismail TF, et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA 2013; 309:896–908.
Halliday B, Gulati A, Ali A, et al. Association between mid-wall late gadolinium enhancement and sudden cardiac death in patients with dilated cardiomyopathy and mild and moderate left ventricular systolic dysfunction. Circulation 2017; 135:2106–2115.
Halliday BP, Baksi AJ, Gulati A, et al. Outcome in dilated cardiomyopathy related to the extent, location, and pattern of late gadolinium enhancement. JACC Cardiovasc Imaging 2018; 12 (8 Pt 2):1645–1655.
Perazzolo Marra M, De Lazzari M, Zorzi A, et al. Impact of the presence and amount of myocardial fibrosis by cardiac magnetic resonance on arrhythmic outcome and sudden cardiac death in nonischemic dilated cardiomyopathy. Hear Rhythm 2014; 11:856–863.
Leong DP, Chakrabarty A, Shipp N, et al. Effects of myocardial fibrosis and ventricular dyssynchrony on response to therapy in new-presentation idiopathic dilated cardiomyopathy: insights from cardiovascular magnetic resonance and echocardiography. Eur Heart J 2012; 33:640–648.
Leyva F, Foley PW, Chalil S, et al. Cardiac resynchronization therapy guided by late gadolinium-enhancement cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2011; 13:29.
Moon JC, Messroghli DR, Kellman P, et al. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson 2013; 15:92.
Puntmann VO, Carr-White G, Jabbour A, et al. T1-mapping and outcome in nonischemic cardiomyopathy: all-cause mortality and heart failure. JACC Cardiovasc imaging 2016; 9:40–50.
Romano S, Judd RM, Kim RJ, et al. Feature-tracking global longitudinal strain predicts death in a multicenter population of patients with ischemic and nonischemic dilated cardiomyopathy incremental to ejection fraction and late gadolinium enhancement. JACC Cardiovasc Imaging 2018; 11:1419–1429.
Merlo M, Masè M, Vitrella G, et al. Usefulness of addition of magnetic resonance imaging to echocardiographic imaging to predict left ventricular reverse remodeling in patients with nonischemic cardiomyopathy. Am J Cardiol 2018; 122:490–497.
Taylor MRG, Carniel E, Mestroni L. Cardiomyopathy, familial dilated. Orphanet J Rare Dis 2006; 1:27.
Heymans S, Eriksson U, Lehtonen J, Cooper LT. The quest for new approaches in myocarditis and inflammatory cardiomyopathy. J Am Coll Cardiol 2016; 68:2348–2364.
Sinagra G, Anzini M, Pereira NL, et al. Myocarditis in clinical practice. Mayo Clin Proc 2016; 91:1256–1266.
Leone O, Veinot JP, Angelini A, et al. 2011 Consensus statement on endomyocardial biopsy from the association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc Pathol 2012; 21:245–274.
Caforio ALP, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013; 34:2636–2648.
Francis R, Lewis C. Myocardial biopsy: techniques and indications. Heart 2018; 104:950–958.
Bulloch RT, Murphy ML, Pearce MB. Intracardiac needle biopsy of the ventricular septum. Am J Cardiol 1965; 16:227–233.
Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease. J Am Coll Cardiol 2007; 50:1914–1931.
Bokhari S, Shahzad R, Castaño A, Maurer SM. Nuclear imaging modalities for cardiac amyloidosis. J Nucl Cardiol 2014; 21:175–184.
Okayama K1, Kurata C, Tawarahara K, Wakabayashi Y, Chida K, Sato A. Diagnostic and prognostic value of myocardial scintigraphy with thallium-201 and gallium-67 in cardiac sarcoidosis. Chest 1995; 107:330–335.
Skali H, Schulman AR, Dorbala S. 18F-FDG PET/CT for the assessment of myocardial sarcoidosis. Curr Cardiol Rep 2013; 15:352.
Flotats A, Carrió I. Cardiac neurotransmission SPECT imaging. J Nucl Cardiol 2004; 11:587–602.
Bengel FM, Higuchi T, Javadi MSLR. Cardiac positron emission tomography. J Am Coll Cardiol 2009; 54:1–11.
Bax JJ, Kraft O, Buxton AE, et al. 123ImIBG scintigraphy to predict inducibility of ventricular arrhythmias on cardiac electrophysiology testing: a prospective multicenter pilot study. Circ Cardiovasc Imaging 2008; 1:131–140.
Al Badarin FJ, Wimmer AP, Kennedy KF, Jacobson AF, Bateman TM. The utility of ADMIRE-HF risk score in predicting serious arrhythmic events in heart failure patients: incremental prognostic benefit of cardiac 123I-mIBG scintigraphy. J Nucl Cardiol 2014; 21:756–762.
Meder B, Haas J, Keller A, et al. Targeted next-generation sequencing for the molecular genetic diagnostics of cardiomyopathies. Circ Cardiovasc Genet 2011; 4:110–122.
Favalli V, Serio A, Grasso M, Arbustini E. Genetic causes of dilated cardiomyopathy. Heart 2016; 102:2004–2014.
Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace 2011; 13:1077–1109.
Hershberger RE, Cowan J, Morales A, Siegfried JD. Progress with genetic cardiomyopathies; screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Heart Fail 2009; 2:253–261.
Mazzarotto F, Tayal U, Buchan RJ, et al. Reevaluating the genetic contribution of monogenic dilated cardiomyopathy. Circulation 2020; 141:387–398.
Corrado D, Basso C, Judge DP. Arrhythmogenic cardiomyopathy. Circ Res 2017; 121:784–802.
Spezzacatene A, Sinagra G, Merlo M, et al. Arrhythmogenic phenotype in dilated cardiomyopathy: natural history and predictors of life-threatening arrhythmias. J Am Heart Assoc 2015; 4:e002149.
Elliott PM, Anastasakis A, Asimaki A, et al. Definition and treatment of arrhythmogenic cardiomyopathy: an updated expert panel report. Eur J Heart Fail 2019; 21:955–964.
Charron P, Arad M, Arbustini E, et al. Genetic counselling and testing in cardiomyopathies: a position statement of the European society of cardiology working group on myocardial and pericardial diseases. Eur Heart J 2010; 31:2715–2728.
van der Bijl P, Bootsma M, Hiemstra YL, Ajmone Marsan N, Bax JJ, Delgado V. Left ventricular 2D speckle tracking echocardiography for detection of systolic dysfunction in genetic, dilated cardiomyopathies. Eur Hear J Cardiovasc Imaging 2019; 20:694–699.
Paldino A, De Angelis G, Merlo M, et al. Genetics of dilated cardiomyopathy: clinical implications. Curr Cardiol Rep 2018; 20:83.
Weintraub RG, Semsarian C, Macdonald P. Dilated cardiomyopathy. Lancet 2017; 6736:1–15.
Herkert JC, Abbott KM, Birnie E, et al. Toward an effective exome-based genetic testing strategy in pediatric dilated cardiomyopathy. Genet Med 2018; 20:1374–1386.
Jasseron C, Lebreton G, Cantrelle C, et al. Impact of heart transplantation on survival in patients on venoarterial extracorporeal membrane oxygenation at listing in France. Transplantation 2016; 100:1979–1987.
Blondheim DS, Jacobs LE, Kotler MN, Costacurta GA, Parry WR. Dilated cardiomyopathy with mitral regurgitation: decreased survival despite a low frequency of left ventricular thrombus. Am Hear J 1991; 122:763–771.
Obadia J-F, Messika-Zeitoun D, Leurent G, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med 2018; 379:2297–2306.
Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med 2018; 379:2307–2318.
Grayburn PA, Sannino A, Packer M. Proportionate and disproportionate functional mitral regurgitation: a new conceptual framework that reconciles the results of the MITRA-FR and COAPT trials. JACC Cardiovasc Imaging 2019; 12:353–362.
Atianzar K, Zhang M, Newhart Z, Gafoor S. Why did COAPT win while MITRA-FR failed? Defining the appropriate patient population for mitraclip. Interv Cardiol 2019; 14:45–47.
Jakovljevic DG, Yacoub MH, Schueler S, et al. Left ventricular assist device as a bridge to recovery for patients with advanced heart failure. J Am Coll Cardiol 2017; 69:1924–1933.
Burkhoff D, Sayer G, Doshi D, Uriel N. Hemodynamics of mechanical circulatory support. J Am Coll Cardiol 2015; 66:2663–2674.
MacGowan GA, Crossland DS, Hasan A, Schueler S. Considerations for patients awaiting heart transplantation – insights from the UK experience. J Thorac Dis 2015; 7:527–531.
Lenneman AJ, Birks EJ. Treatment strategies for myocardial recovery in heart failure. Curr Treat Options Cardiovasc Med 2014; 16:287.
Shehab S, Macdonald PS, Keogh AM, et al. Long-term biventricular HeartWare ventricular assist device support – case series of right atrial and right ventricular implantation outcomes. J Heart Lung Transplant 2016; 35:466–473.
Mehra MR, Canter CE, Hannan MM, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. J Heart Lung Transplant 2016; 35:1–23.
Bhagra SK, Pettit S, Parameshwar J. Cardiac transplantation: indications, eligibility and current outcomes. Heart 2019; 105:252–260.
Lund LH, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: thirty-second official adult heart transplantation report–2015; focus theme: early graft failure. J Heart Lung Transplant 2015; 34:1244–1254.
Dipchand AI, Rossano JW, Edwards LB, et al. The Registry of the International Society for Heart and Lung Transplantation: eighteenth official pediatric heart transplantation report–2015; focus theme: early graft failure. J Heart Lung Transplant 2015; 34:1233–1243.
Zecchin M, Merlo M, Pivetta A, et al. How can optimization of medical treatment avoid unnecessary implantable cardioverter-defibrillator implantations in patients with idiopathic dilated cardiomyopathy presenting with ‘sCD-HeFT Criteria?’. Am J Cardiol 2012; 109:729–735.
Merlo M, Pyxaras SA, Pinamonti B, Barbati G, Di Lenarda A, Sinagra G. Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment. J Am Coll Cardiol 2011; 57:1468–1476.
Kubanek M, Sramko M, Maluskova J. Novel predictors of left ventricular reverse remodeling in individuals with recent-onset dilated cardiomyopathy. J Am Coll Cardiol 2013; 61:54–63.
Dal Ferro M, Stolfo D, Altinier A, et al. Association between mutation status and left ventricular reverse remodelling in dilated cardiomyopathy. Heart 2017; 103:1704–1710.
Halliday BP, Cleland JGF, Goldberger JJ, Prasad SK. Personalizing risk stratification for sudden death in dilated cardiomyopathy. Circulation 2017; 136:215–231.
Di Marco A, Anguera I, Schmitt M, et al. Late gadolinium enhancement and the risk for ventricular arrhythmias or sudden death in dilated cardiomyopathy. JACC Hear Fail 2017; 5:28–38.
Nakamori S, Bui AH, Jang J, et al. Increased myocardial native T1 relaxation time in patients with nonischemic dilated cardiomyopathy with complex ventricular arrhythmia. J Magn Reson Imaging 2018; 47:779–786.
Hasselberg NE, Haland TF, Saberniak J, et al. Lamin A/C cardiomyopathy: young onset, high penetrance, and frequent need for heart transplantation. Eur Heart J 2018; 39:853–860.
van Rijsingen IAW, Arbustini E, Elliott PM, et al. Risk factors for malignant ventricular arrhythmias in lamin A/C mutation carriers. J Am Coll Cardiol 2012; 59:493–500.
Begay RL, Graw SL, Sinagra G, et al. Filamin C truncation mutations are associated with arrhythmogenic dilated cardiomyopathy and changes in the cell–cell adhesion structures. JACC Clin Electrophysiol 2018; 4:504–514.
Parikh VN, Caleshu C, Reuter C, et al. Regional variation in RBM20 causes a highly penetrant arrhythmogenic cardiomyopathy. Circ Hear Fail 2019; 12:e005371.
Brauch KM, Karst ML, Herron KJ, et al. Mutations in ribonucleic acid binding protein gene cause familial dilated cardiomyopathy. J Am Coll Cardiol 2009; 54:930–941.
McNair WP, Sinagra G, Taylor MRG, et al. SCN5A mutations associate with arrhythmic dilated cardiomyopathy and commonly localize to the voltage-sensing mechanism. J Am Coll Cardiol 2011; 57:2160–2168.
Piccini JP, Allen LA, Kudenchuk PJ, Page RL, Patel MR, Turakhia MP. Wearable cardioverter-defibrillator therapy for the prevention of sudden cardiac death: a science advisory from the american heart association. Circulation 2016; 133:1715–1727.
Salehi N, Nasiri M, Bianco NR, et al. The wearable cardioverter defibrillator in nonischemic cardiomyopathy: a us national database analysis. Can J Cardiol 2016; 32:1247.e1–1247.e6.
Merlo M, Stolfo D, Anzini M, et al. Persistent recovery of normal left ventricular function and dimension in idiopathic dilated cardiomyopathy during long-term follow-up: does real healing exist? J Am Heart Assoc 2015; 4:e001504.
Mann DL, Barger PM, Burkhoff D. Myocardial recovery and the failing heart: myth, magic, or molecular target? J Am Coll Cardiol 2012; 60:2465–2472.
Zecchin M, Proclemer AA, Magnani S, et al. Long-term outcome of ‘super-responder’ patients to cardiac resynchronization therapy. Europace 2014; 16:363–371.
Halliday BP, Wassall R, Lota AS, et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet 2019; 393:61–73.